HBHannah L. Brooks

Hannah L. Brooks

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hannah L. Brooks has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • “It’s a Donut!” – Veterans’ perspectives of lung cancer screening with low-dose computed tomography

    by Camden Castagna-McLeod, Hannah L. Brooks, Kemberlee A. Bonnet, Carolyn M. Audet, Miranda Sue Terry, Hilary A. Tindle, David Schlundt, Sally York, Fred Hendler, Drew Moghanaki, et al.

  • Open Access

    Ensuring that people who use drugs are safely and equitably included at meetings and conferences

    by Hannah L Brooks, Shay J. Vanderschaeghe, Nicole D. Gehring, Shanell Twan, Marliss Taylor, Elaine Hyshka

    Collaborating with people who use or used drugs (PWUD) in research and policy fora and incorporating their perspectives in decision-making processes is a crucial step towards mitigating drug policy-related harm. PWUD are experts in drug use and equipped to share their experiences and knowledge and impact drug policy change. However, equitable inclusion of PWUD in conferences and other fora is typically inadequate. PWUD were central participants in the planning and implementation of the Stimulus 2018: Drugs, Policy, and Practice conference. Conference planners made considerable effort to ensure PWUD attendees had their physical and emotional needs met, including access to overdose prevention services. However, guidance is needed to better safeguard the physical and mental health of conference attendees who use drugs. This Research & Practice Note aims to initiate discussion on this underexplored topic and provide ideas for the safer inclusion of PWUD within research and policy fora.

  • Open Access

    Patients’ Information Needs for Informed Consent to Participate in First‐in‐Human Pig Kidney Xenotransplant Clinical Trials: A Mixed Methods Study

    by Elisa J. Gordon, Michael K. Gusmano, Jessica Gacki‐Smith, Hannah L. Brooks, Margaret M. Matthews, Dahlya Manning, Joseph Leventhal, Karen J. Maschke

    Background: Transplant programs preparing to initiate first‐in‐human pig kidney xenotransplant clinical trials must be especially careful when obtaining participants’ informed consent. Little is known about the kind of information patients want for making an informed decision about trial participation. Methods: We conducted semi‐structured telephone interviews with waitlisted kidney transplant patients about information needs regarding participating in a first‐in‐human pig kidney xenotransplant trial, which guided development of a prototype consent form. Subsequent usability testing interviews sought patient feedback on the consent form. We analyzed qualitative data by thematic analysis and quantitative data by descriptive statistics. Results: Twenty‐eight patients participated in semi‐structured interviews; 16 patients participated in usability testing interviews. Most interview participants were male (68%, 56%), White (54%, 56%), or Black (36%, 31%), respectively. Interview participants identified five types of information needs: (1) the potential for infection contraction and transmission; (2) risks, benefits, and impact of xenotransplant trials; (3) xenotransplant clinical trial and recipient experience; (4) clinical trial logistics; and (5) the pig and its kidney. Usability testing participants suggested adding details to the prototype. Participants’ preparedness to make a decision about participating in a xenotransplant trial increased after reviewing the prototype (12.5% vs. 31.3%, n.s.). Conclusion: We identified multiple unique types of information patients desired to make informed decisions about pig kidney xenotransplant trial participation. Transplant programs initiating xenotransplant trials should be prepared to address patients’ information needs to optimize informed decision‐making for trial participation. The prototype consent form may support a patient‐centered approach to informed consent.


  • Open Access

    Transplant Patients’ Perceptions About Participating in First‐in‐Human Pig Kidney Xenotransplant Clinical Trials: A Mixed Methods Study

    by Elisa J. Gordon, Karen J. Maschke, Jessica Gacki‐Smith, Hannah L. Brooks, Margaret M. Matthews, Karen Traboulsi, Dahlya Manning, Joseph Leventhal, Michael K. Gusmano

    First‐in‐human pig xenotransplant clinical trials may soon begin, which raises ethical concerns about patients’ decision‐making to participate in such trials. We assessed kidney transplant candidates’ attitudes and hypothetical decision‐making about participating in xenotransplant trials through semi‐structured telephone interviews and an online survey. We analyzed qualitative data by thematic analysis and quantitative data by descriptive statistics. Twenty‐eight patients participated in interviews; 142 patients participated in the survey. Most interview and survey respondents were male (68%, 56%), White (54%, 61%), or Black (36%, 22%). Although interview participants appreciated xenotransplantation research's potential to advance science, they expressed concerns about infection transmission and graft function. Few survey respondents were willing to participate in a pig kidney trial to test the safety of pig kidneys (12.6%) or pig kidney function (16.9%). Interview participants would be more likely to participate in a first‐in‐human pig kidney trial if receiving a human kidney was unlikely and their health status declined. Willingness would also depend on how long the pig kidney would function. Most interview participants were receptive to long‐term monitoring, but not to family monitoring. Transplant programs planning xenotransplant trials should anticipate these types of concerns for optimizing human subject protections and conducting a robust informed consent process.


  • Open Access

    Temporal and other factors that influence the time doctors take to prescribe using an electronic prescribing system

    by Jamie J Coleman, James Hodson, Sarah K Thomas, Hannah L Brooks, Robin E Ferner

    Background A computerized physician order entry (CPOE) system with embedded clinical decision support can reduce medication errors in hospitals, but might increase the time taken to generate orders. Aims We aimed to quantify the effects of temporal (month, day of week, hour of shift) and other factors (grade of doctor, prior experience with the system, alert characteristics, and shift type) on the time taken to generate a prescription order. Setting A large university teaching hospital using a locally developed CPOE system with an extensive audit database. Design We retrospectively analyzed prescription orders from the audit database between August 2011 and July 2012. Results The geometric mean time taken to generate a prescription order within the CPOE system was 11.75 s (95% CI 11.72 to 11.78). Time to prescribe was most affected by the display of high-level (24.59 s (24.43 to 24.76); pConclusions The display of alerts, prescribing experience, system familiarity, and environment all affect the time taken to generate a prescription order. Our study reinforces the need for appropriate alerts to be presented to individuals at an appropriate place in the workflow, in order to improve prescribing efficiency.